Welcome to our dedicated page for Biohaven news (Ticker: BHVN), a resource for investors and traders seeking the latest updates and insights on Biohaven stock.
Biohaven Ltd. (NYSE: BHVN) is a clinical-stage biopharmaceutical company whose news flow centers on progress across its immunology, obesity, neuroscience and oncology pipelines. Company updates frequently cover clinical trial readouts, regulatory interactions, financing events and scientific presentations that shape the outlook for its drug development platforms.
Investors and followers of BHVN news can expect detailed announcements on Biohaven’s Kv7 ion channel modulation programs, including opakalim in refractory focal epilepsy and major depressive disorder, as well as updates on the MoDE™ and TRAP™ extracellular degrader platforms targeting immune-mediated diseases such as IgA nephropathy and Graves’ disease. News releases also highlight the advancement of taldefgrobep alfa, a myostatin-activin pathway inhibitor in obesity and SMA, and BHV-8000, a brain-penetrant TYK2/JAK1 inhibitor in pivotal studies for early Parkinson’s disease.
Biohaven’s oncology news often focuses on early clinical data from its next-generation antibody-drug conjugates, including BHV-1510, a Trop2-directed ADC, and BHV-1530, an FGFR3-directed ADC, with reports of tumor responses, safety profiles and combination strategies with checkpoint inhibitors. Additional coverage includes regulatory milestones such as the FDA Complete Response Letter for VYGLXIA (troriluzole) in spinocerebellar ataxia and the company’s stated plans for further regulatory dialogue.
Capital markets and corporate updates—such as public offerings of common shares, at-the-market transactions, portfolio reprioritization and cost-optimization measures—also feature prominently in BHVN news. Readers who monitor this stream gain insight into Biohaven’s evolving clinical strategy, key upcoming milestones and how the company allocates resources across its late-stage programs.
Biohaven (NYSE: BHVN) highlighted early clinical progress across multiple programs at the 44th Annual J.P. Morgan Healthcare Conference on Jan 12, 2026. Key clinical observations include rapid, selective lowering of pathogenic Gd-IgA1 (>60% mean reduction within hours; max >80%) with BHV-1400 and associated hematuria resolution, >60% proteinuria reduction and a 24% eGFR increase in one patient. BHV-1300 produced up to an 87% IgG reduction and suppression of pathogenic TSHR antibodies with thyroid hormone normalization. Opakalim showed a 55% ≥50% responder rate at 75 mg in the OLE. Multiple pivotal studies and topline readouts are anticipated in 2026.
Biohaven (NYSE: BHVN) announced that Vlad Coric, M.D., Chairman and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PST (11:15 a.m. EST). The presentation is scheduled for The Westin St. Francis Hotel in San Francisco, California.
Biohaven (NYSE: BHVN) reported results from a Phase 2 proof-of-concept study of BHV-7000 in major depressive disorder (MDD) on Dec. 24, 2025. The study did not meet its primary endpoint (change in MADRS over six weeks versus placebo). Trends favoring BHV-7000 were observed in some clinically relevant subgroups, including participants with more severe depression at screening and baseline. Overall safety was acceptable: adverse events were mostly mild or moderate and largely resolved, with headache (10.7% vs 9.9%) and nausea (4.2% vs 5.6%) as the only events >5% in any arm. Additional analyses are ongoing and Biohaven will present updates at the J.P. Morgan Healthcare Conference in Jan 2026. The company does not plan additional psychiatric trials in 2026 to prioritize immunology, obesity, and epilepsy programs.
Biohaven (NYSE: BHVN) presented Phase 1 data for BHV-1510, a next‑generation Trop2 antibody‑drug conjugate, in combination with Regeneron’s anti‑PD‑1 cemiplimab at ESMO IO (Dec 10–12, 2025).
At the 2.5 mg/kg Q3W BHV‑1510 dose, confirmed objective response rate (ORR) was 72.7% with confirmed responses including 3/5 NSCLC (60%), 4/4 endometrial cancer (100%, including a CR) and 1/2 urothelial (50%). Across 23 efficacy‑evaluable participants the confirmed ORR was 52.2%. Median time to response was 11.1 weeks. Safety showed low rates of payload‑related toxicities, no interstitial lung disease, no treatment discontinuations for AEs, and a favorable PK with unconjugated payload payload‑to‑ADC molar ratio <1%.
Biohaven (NYSE: BHVN) closed an upsized underwritten public offering on Nov 13, 2025 of 26,833,334 common shares at $7.50 per share, which included the full exercise of the underwriters' option to purchase 3,500,000 additional shares. The offering was upsized from a previously announced $150 million to $175 million and generated approximately $200 million in gross proceeds before fees and expenses.
Biohaven intends to use net proceeds for general corporate purposes. The shares were issued under an effective Form S-3 shelf registration; J.P. Morgan, Goldman Sachs, Leerink Partners, TD Cowen and Cantor acted as book-runners.
Biohaven (NYSE: BHVN) priced an underwritten public offering of 23,333,334 common shares at $7.50 per share, with gross proceeds of approximately $175 million. The underwriters have a 30-day option to buy up to 3,500,000 additional shares at the public price less discounts and commissions.
The offering is expected to close on November 13, 2025, subject to customary conditions. Biohaven intends to use net proceeds for general corporate purposes. The shares will be issued under an effective Form S-3 shelf registration.
Biohaven (NYSE: BHVN) announced on November 11, 2025 that it has commenced an underwritten public offering of $150 million of common shares, with a 30-day underwriter option to purchase up to an additional $22.5 million of shares at the public offering price, less underwriting discounts and commissions.
The offering is subject to market and other conditions and may not be completed. All shares will be sold by Biohaven and will be issued under an effective Form S-3 shelf registration. Net proceeds are intended for general corporate purposes. J.P. Morgan and Goldman Sachs are book-running managers.
Biohaven (NYSE: BHVN) reported Q3 2025 results and strategic reprioritization on Nov 10, 2025. The company recorded a GAAP net loss of $173.4M ($1.64/share) and a non-GAAP adjusted net loss of $155.9M ($1.47/share). Cash, cash equivalents, marketable securities and restricted cash totaled $263.8M as of Sept 30, 2025. Biohaven initiated cost optimization to focus on three late-stage value-driving programs: opakalim (Kv7 activator for focal epilepsy and MDD), lead TRAP/MoDE degraders (BHV-1400 for IgAN, BHV-1300 for Graves' disease) and taldefgrobep alfa (myostatin-activin inhibitor for obesity and SMA).
Management expects ~60% reduction in annual direct R&D spend and milestone timing including top-line MDD results in 4Q 2025, focal epilepsy results in 1H 2026, and a Phase 2 obesity start in 4Q 2025.
Biohaven (NYSE: BHVN) received an FDA Complete Response Letter (CRL) for the NDA seeking approval of VYGLXIA (troriluzole) for spinocerebellar ataxia (SCA) on Nov 5, 2025.
Key data in the filing included a 3‑year real‑world evidence study showing a 50–70% slowing of SCA progression and a safety analysis showing >50% reduction in fall risk versus placebo, but FDA raised concerns about RWE/external control bias and study design.
Biohaven will request a meeting with FDA, continue an expanded access program, and is cutting non‑priority R&D to prioritize three late‑stage programs while targeting an ≈60% reduction in annual direct R&D spend.
Biohaven (NYSE: BHVN) reported Q2 2025 financial results and business developments, highlighting a cash position of $408.2 million as of June 30, 2025. Key developments include promising clinical results across multiple platforms: MoDE degrader BHV-1300 achieved up to 87% IgG reduction, while TRAP degrader BHV-1400 demonstrated over 80% Gd-IgA1 reductions.
The company's oncology program showed early success with BHV-1510, their Trop2 ADC, achieving tumor reduction in all initial 6 patients when combined with cemiplimab. Additionally, Biohaven initiated a pivotal Phase 2/3 study for BHV-8000 in Parkinson's disease and awaits FDA decision on VYGLXIA for spinocerebellar ataxia in Q4 2025.
Financial results showed R&D expenses of $184.4 million, down from $314.8 million in Q2 2024, with a net loss of $198.1 million ($1.94 per share) compared to $319.8 million ($3.64 per share) in the prior year.
FAQ
What is the current stock price of Biohaven (BHVN)?
What is the market cap of Biohaven (BHVN)?
